Axsome Therapeutics (AXSM) Other Non-Current Liabilities (2017 - 2026)

Axsome Therapeutics (AXSM) has 7 years of Other Non-Current Liabilities data on file, last reported at $73.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 18.61% year-over-year to $73.7 million; the trailing twelve-month figure through Mar 2026 stood at $73.7 million (down 18.61% YoY), and the FY2025 full-year result was $77.5 million, down 15.42% from the prior year.
• Other Non-Current Liabilities fell to $73.7 million in Q1 2026, from $77.5 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $91.7 million in Q4 2024 to a low of $27.4 million in Q3 2022.
• A 5-year average of $61.3 million and a median of $71.6 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities jumped 163.01% in 2024 and decreased 18.61% in 2026, its largest moves.
• Tracing AXSM's Other Non-Current Liabilities over 5 years: stood at $31.1 million in 2022, then soared by 135.69% to $73.3 million in 2023, then climbed by 25.08% to $91.7 million in 2024, then declined by 15.42% to $77.5 million in 2025, then declined by 4.91% to $73.7 million in 2026.
• Business Quant data shows AXSM's Other Non-Current Liabilities at $73.7 million in Q1 2026, $77.5 million in Q4 2025, and $89.9 million in Q3 2025.